Shots:

• The P-III study involves assessing of Truxima vs Rituxan in 140 patients with AFL for 40mos. across India- Japan- Russia- and the EU- including Germany and Spain
• The P-III study results: @4yrs. OS (88% vs 93.4%); PFS (60.9% vs 54.7%); TTP (64.2% vs 60.9%)- presented at ASH2019
• Celltrion has launched Truxima in the US via Teva and is the first rituximab biosimilar in the US with an annual sale of $4.2B

Click here to read full press release/ article | Ref: Korea Biomed | Image: Celltrion